Stroke, Acute
Conditions
Keywords
rehabilitation
Brief summary
The purpose of this clinical pilot study is to evaluate the effects of the MR-010 on tolerability, biomechanics and walking speed in the acute stroke care setting in addition to its impact on length of stay.
Interventions
DEVICEMR-010
MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
Sponsors
MedRhythms, Inc.
University of Massachusetts, Worcester
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must be 18 years of age or older. * Must be able to read and speak English fluently. * Be within 24 hours from admission for confirmed stroke event. * Currently able to walk at a speed greater or equal to 0.4m/s, but less than 1.0m/s, as determined by a 10-meter walk test for comfortable walking speed (the average of three trials). * Demonstrates some level of asymmetry in gait. * Is expected to be discharged from the acute care setting requiring physical therapy per standard of care and participant has verbally committed to receiving at least one therapy session. * Able and willing to consent with proposed study schema (verbal commitment), including consent to participate in communication with the treating clinician (as needed) during the study period. * Score ≤1 on question 1b and a 0 on question 1c on the NIH Stroke Scale. * Able to safely participate in protocol-defined walking therapy sessions of 30-minute duration as determined by the Investigator.
Exclusion criteria
* Participant unable or unwilling to provide informed consent. * Has a known history of neurologic (excluding stroke) injury. * Has severe aphasia and/or a speech/language disorder, limiting ability to express needs and comprehend instructions. * Has an external lower limb prosthetic (artificial limb). * Has a hearing impairment. * Had orthopedic surgery in the last year. * Has co-morbidities that prevent participation in exercise (for example: musculoskeletal, cardiovascular, pulmonary and neurological - other than stroke). * Vulnerable populations as deemed inappropriate for study by site Principal Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Gait Speed (m/s) | 90 days | Change in gait speed (m/s) from baseline to study completion as measured by a 6 meter walking test. |
| Adherence to MR-010 Therapy Schedule | 90 days | Adherence to the MR-010 therapy schedule is measured by the number of participants who completed scheduled sessions (3 times per week for 12 weeks) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of Stay | Duration of hospital stay, up to 14 days | Median length of stay in acute stroke hospital |
| Readmission to Hospital | 90 days | Percent of readmission to hospital following discharge |
Countries
United States
Participant flow
Recruitment details
Recruited in hospital after confirmed diagnosis of acute stroke from 11/03/2021 to 11/27/2022. Study terminated due to lower than expected recruitment
Pre-assignment details
Patients included following diagnosis of acute stroke
Participants by arm
| Arm | Count |
|---|---|
| MR-010 Walking Therapy Subjects will use the MR-010 three times a week for 30 minutes per session for 90 days. Subjects will undergo a 10-meter walk test bi-weekly and at 45 and 90 days.
MR-010: MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat. | 2 |
| Standard of Care Subjects will undergo a 10-meter walk test bi-weekly for 90 days and at 45 and 90 days | 2 |
| Total | 4 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Participants declined to participate in the interventions per protocol | 2 | 0 |
Baseline characteristics
| Characteristic | MR-010 Walking Therapy | Standard of Care | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 1 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 1 Participants | 1 Participants |
| Age, Continuous | 66.5 years | 67.5 years | 67 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 2 Participants | 4 Participants |
| Region of Enrollment United States | 2 participants | 2 participants | 4 participants |
| Sex: Female, Male Female | 0 Participants | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 2 Participants | 1 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 2 | 0 / 2 |
| other Total, other adverse events | 0 / 2 | 0 / 2 |
| serious Total, serious adverse events | 0 / 2 | 0 / 2 |
Outcome results
Primary
Adherence to MR-010 Therapy Schedule
Adherence to the MR-010 therapy schedule is measured by the number of participants who completed scheduled sessions (3 times per week for 12 weeks)
Time frame: 90 days
Population: Data for this outcome was only intended to be collected and measured for participants in the MR-010 walking therapy group. As no participants completed the MR-101 walking therapy intervention, no data was collected.
Primary
Change in Gait Speed (m/s)
Change in gait speed (m/s) from baseline to study completion as measured by a 6 meter walking test.
Time frame: 90 days
Population: No subjects completed the at home 6 Meter Walking Test. Therefore, no data was collected for this outcome measure.
Secondary
Length of Stay
Median length of stay in acute stroke hospital
Time frame: Duration of hospital stay, up to 14 days
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MR-010 Walking Therapy | Length of Stay | 3 days |
| Standard of Care | Length of Stay | 3 days |
Secondary
Readmission to Hospital
Percent of readmission to hospital following discharge
Time frame: 90 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| MR-010 Walking Therapy | Readmission to Hospital | 0 Participants |
| Standard of Care | Readmission to Hospital | 0 Participants |